protoporphyrin IX Inhibitors
1 drugsAbout protoporphyrin IX
Protoporphyrin IX is a precursor in heme and chlorophyll synthesis. While normally quickly converted, its accumulation can be exploited for therapeutic benefit.
Currently, protoporphyrin IX is targeted by one FDA-approved drug, AMELUZ. There is no genetic evidence data available for this target.
AMELUZ (BIOFRONTERA) is a small molecule approved in 2016 for one indication in the 'other' therapeutic area.
Top protoporphyrin IX Drugs
BIOFRONTERA is the only company with an approved drug targeting protoporphyrin IX.
Low competition may indicate high barriers to entry or limited market potential.
protoporphyrin IX Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets protoporphyrin IX, using small molecule modality.
The exclusive use of small molecules suggests an opportunity for other modalities.
protoporphyrin IX Clinical Trials 31 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on protoporphyrin IX. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 4 | 3 | 1 | 57% |
| Phase 2 | 14 | 5 | 6 | 3 | 45% |
| Phase 3 | 4 | 0 | 1 | 3 | 0% |
| Phase 4 | 5 | 3 | 1 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
protoporphyrin IX Drug Approval Timeline (2016 - 2016)
The first and most recent drug approval was AMELUZ in 2016.
A single approval in 2016 suggests a potentially stagnant or niche market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on protoporphyrin IX. A trial counts if an approved drug acting on protoporphyrin IX is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.